arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

ADIAL PHARMACEUTICALS, INC.

ADIL

$3.86 ▼ -1.02 (-20.90%) at close

10 Visible periods

19 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

ADIAL PHARMACEUTICALS, INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $2.6M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -116.8% ↗

FCF / Share $-9.71 ↗

Trailing P/E —

Price / Book 0.8x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

10-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-7.98M

↑ +39.6% —

FCF / Share Free cash flow per share

$-9.71

↑ +72.8% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↑

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
EPS Growth YoY (%)	82.5% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-1789.2% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-605.9% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	51.0% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—
Net Income Growth YoY (%)	39.6% Excellent ↑ Excellent Improving Year-over-year change in net income	-157.6% Weak ↓ Weak Declining Year-over-year change in net income	59.8% Excellent ↑ Excellent Improving Year-over-year change in net income	34.5% Excellent ↑ Excellent Improving Year-over-year change in net income	-78.3% Weak ↑ Weak Improving Year-over-year change in net income	-26.8% Weak ↑ Weak Improving Year-over-year change in net income	26.1% Excellent Excellent Year-over-year change in net income	-920.8% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	72.8% Excellent Excellent Year-over-year change in free cash flow	—	—	30.9% Excellent Excellent Year-over-year change in free cash flow	—	—	—	—	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Effective Tax Rate (%) (%)	—	—	—	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.5% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—	—	—
FCF / Net Income (x)	0.81x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.52x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	1.33x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	0.88x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.62x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	0.70x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.74x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.21x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.43x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Return on Invested Capital (%)	-116.8% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-160.9% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-133.3% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-406.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-547.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-216.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-91.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-124.3% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	78.8% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-116.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-164.2% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-145.4% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-232.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-258.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-199.0% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-107.4% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-148.7% Weak Weak Operating profit relative to total assets Optimal: > 10%	-2881.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-151.2% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1108%)	—	-125.5% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-936%)	—	—	-273.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1922%)	-120.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-902%)	-261.9% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1846%)	114.2% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+662%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Interest Coverage (x)	—	—	—	—	—	—	—	-183.10x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—
Net Debt (USD)	$-5.88M	$-3.75M	$-2.83M	$-4.00M	$-6.06M	$-4.40M	$-6.78M	$-3.87M	$-18.25K	$-87.99K

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Basic EPS, GAAP (USD)	$-11.93	$-68.01	$-3.60	$-0.51	$-1.04	—	—	—	—	—
Free Cash Flow per Share (USD)	$-9.71	$-35.67	—	$-0.45	$-0.65	—	—	—	—	—
Book Value per Share (USD)	$4.75	$15.72	$2.45	$0.12	$0.17	$0.28	$0.69	$0.65	$-0.31	—
Tangible Book Value per Share (USD)	$4.75	$15.70	$2.45	$0.11	$0.16	$0.28	$0.69	$0.65	$-0.31	—
Basic Weighted Avg Shares (shares)	668,630	194,059	—	25.04M	18.59M	—	—	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Working Capital (USD)	$4.78M	$3.08M	$2.55M	$2.99M	$3.74M	$3.63M	$7.13M	$4.43M	$-1.00M	—
Total Equity (USD)	$5.28M	$4.07M	$4.08M	$3.28M	$3.51M	$3.99M	$7.14M	$4.44M	$-997.55K	$-103.49K

📋 What is driving earnings? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Net Income, GAAP (USD)	$-7.98M	$-13.20M	$-5.12M	$-12.73M	$-19.42M	$-10.89M	$-8.59M	$-11.63M	$-1.14M	—
Operating Cash Flow (USD)	$-6.49M	$-6.92M	$-6.81M	$-11.19M	$-11.95M	$-7.63M	$-6.34M	$-2.50M	$-494.86K	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 10 years · 38 quarters

ADIAL PHARMACEUTICALS, INC.

Analytical Summary

10-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare ADIL with peers